Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UTHR | CLUSTER | neutral | 4/10 | CEO Martine Rothblatt sold ~$7.5M in open-market shares over three days (Sep 14-16), following a $477.6M accelerated sha | Sep 18, 2026 |
| NEUP | DEFA14A | neutral | 3/10 | Neuphoria Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, alongsi | Sep 18, 2026 |
| NEUP | DEF 14A | neutral | 3/10 | Neuphoria Therapeutics Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held | Sep 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new real-world data at Psych Congress showing that UZEDY (risperidone) extended-release injectable suspen | Sep 18, 2026 |
| OTLK | 8-K | neutral | 3/10 | Outlook Therapeutics announced the U.S. wholesale acquisition cost (WAC) for LYTENAVA at $485 per vial on September 16, | Sep 18, 2026 |
| BYSI | 8-K | bearish | 7/10 | BeyondSpring received a Nasdaq deficiency notice on September 17, 2026, for failing to maintain a minimum $1.00 closing | Sep 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting in | Sep 18, 2026 |
| ADIL | 8-K | neutral | 4/10 | Adial Pharmaceuticals held its 2026 Annual Meeting on September 17, 2026, where stockholders approved the 2026 Equity In | Sep 18, 2026 |
| ETRA | 3 | neutral | 2/10 | Matthew Fust filed a Form 3 initial statement of beneficial ownership with Electra Therapeutics, Inc., disclosing stock | Sep 18, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders at Arcutis Biotherapeutics sold a combined $206K in open-market sales over a one-week window. Director Howa | Sep 18, 2026 |
| ETRA | 3 | neutral | 2/10 | Carl L. Gordon, a director and OrbiMed affiliate, filed a Form 3 initial statement of beneficial ownership with Electra | Sep 18, 2026 |
| FLNA | 8-K | bearish | 7/10 | Filana Therapeutics received a Nasdaq deficiency notice on September 17, 2026, because its common stock bid price closed | Sep 18, 2026 |
| MPLT | S-1/A | neutral | 4/10 | MapLight Therapeutics filed Amendment No. 1 to its S-1 registration statement, solely to correct the number of shares ou | Sep 18, 2026 |
| NCEL | 6-K | bearish | 6/10 | NewcelX Ltd. filed its unaudited interim financial statements for H1 2026, reporting a net loss of $2.9M (vs $11.3M in H | Sep 18, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 2/10 | Zenas BioPharma granted inducement stock options and RSUs to new hires under Nasdaq Rule 5635(c)(4). The grants are rout | Sep 18, 2026 |
| BBIO | PRESS-RELEASE | neutral | 2/10 | BridgeBio Pharma granted 63,009 restricted stock units to 36 new employees as an inducement material to their employment | Sep 18, 2026 |
| GERN | PRESS-RELEASE | neutral | 2/10 | Geron Corporation granted inducement stock options for 821,250 shares to nine newly hired employees at $1.32 per share, | Sep 18, 2026 |
| AMRX | PRESS-RELEASE | bullish | 6/10 | Amneal Pharmaceuticals received FDA approval for its lanreotide injection (120 mg/0.5 mL), a generic version of Somatuli | Sep 18, 2026 |
| XBIO | SC 13G | neutral | 2/10 | MJL Manager LLC and its control person Michael Liu filed a Schedule 13G disclosing a passive stake in Xenetic Bioscience | Sep 18, 2026 |
| EXOZ | 8-K | neutral | 1/10 | Exozymes Inc. filed an 8-K solely to announce the date of its 2026 annual meeting (November 13, 2026) and the related pr | Sep 18, 2026 |
| HYEX | 8-K | neutral | 2/10 | Director Bill Croyle resigned from the board of Healthy Extracts Inc. on September 13, 2026. His board and committee pos | Sep 18, 2026 |
| BTMD | SC 13G/A | neutral | 4/10 | Amit Mohan Agarwal filed an amended Schedule 13G on 2026-09-18, reporting a passive stake of 2,400,000 shares (8.37% of | Sep 18, 2026 |
| TCRT | PRESS-RELEASE | bearish | 5/10 | Alaunos Therapeutics announced a registered direct offering of ~767K shares (common + pre-funded warrants) at $1.46/shar | Sep 18, 2026 |
| SILO | PRESS-RELEASE | bullish | 5/10 | Silo Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering its lead asset SPC-15, an in | Sep 18, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 4/10 | TOMI Environmental Solutions reported Q2 2026 EPS of -$0.05, beating consensus of -$0.11 by 55.4%, but revenue was not d | Sep 18, 2026 |
| HALO | 8-K | mixed | 6/10 | Halozyme priced an upsized $1.3 billion private offering of 1.50% convertible senior notes due 2033, with an additional | Sep 18, 2026 |
| XRTX | 6-K | neutral | 4/10 | XORTX announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulation of oxypurin | Sep 18, 2026 |
| XRTX | PRESS-RELEASE | neutral | 4/10 | XORTX Therapeutics announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulatio | Sep 18, 2026 |
| ELAB | 8-K | neutral | 4/10 | PMGC Holdings Inc. (ELAB) announced a binding payment agreement with Longevity Health Holdings to convert the 5% net sal | Sep 18, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings entered a payment agreement with Longevity Health Holdings converting its 5% net sales royalty from the El | Sep 18, 2026 |